[go: up one dir, main page]

CY1109790T1 - Παραγωγα συντηγμενου αζολιου-πυριμιδινης - Google Patents

Παραγωγα συντηγμενου αζολιου-πυριμιδινης

Info

Publication number
CY1109790T1
CY1109790T1 CY20091100017T CY091100017T CY1109790T1 CY 1109790 T1 CY1109790 T1 CY 1109790T1 CY 20091100017 T CY20091100017 T CY 20091100017T CY 091100017 T CY091100017 T CY 091100017T CY 1109790 T1 CY1109790 T1 CY 1109790T1
Authority
CY
Cyprus
Prior art keywords
disease
present
diseases
derivatives
disorders
Prior art date
Application number
CY20091100017T
Other languages
English (en)
Inventor
Mitsuyuki Shimada
Toshiki Murata
Kinji Fuchikami
Hideki Tsujishita
Naoki Omori
Issei Kato
Mami Miura
Klaus Urbahns
Florian Gantner
Kevin Bacon
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of CY1109790T1 publication Critical patent/CY1109790T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αφορά νέα παράγωγα συντηγμένης αζολοπυριμιδίνης, μεθόδους παρασκευής αυτών και φαρμακευτικά παρασκευάσματα που περιέχουν αυτές. Τα παράγωγα συντηγμένης αζολοπυριμιδίνης της παρούσας εφεύρεσης δεικνύουν αυξημένη ισχύ για αναστολή φωσφοτιδυλινοσιτόλης-3-κινάσης (ΡΙ3Κ), ειδικά για αναστολή Ρ13Κ-γ και μπορεί να χρησιμοποιηθούν για την προφύλαξη και θεραπεία ασθενειών που συνδυάζονται με ΡΙ3Κ και ιδιαιτέρως με δραστικότητα Ρ13Κ-γ. Ειδικότερα, τα παράγωγα αζολίου της παρούσας εφεύρεσης είναι χρήσιμα για θεραπεία και προφύλαξη ασθενειών ως εξής: φλεγμονωδών και ανοσορυθμιστικών διαταραχών, όπως άσθματος, ατοπικής δερματίτιδας, ρινίτιδας, αλλεργικών ασθενειών, χρόνιας αποφρακτικής πνευμονοπάθειας (COPD), σηψαιμικού σοκ, ασθενειών συνδέσμου, αυτοάνοσων παθολογιών, όπως ρευματοειδούς αρθρίτιδας και ασθένειας Graves, καρκίνου, διαταραχών μυοκαρδιακής συσταλτικότητας, καρδιακής ανεπάρκειας, θρομβοεμβολισμού, ισχαιμίας και αθηροσκλήρωσης. Οι ενώσεις της παρούσας εφεύρεσης είναι επίσης χρήσιμες για πνευμονική υπέρταση, νεφρική ανεπάρκεια, καρδιακή υπερτροφία, καθώς επίσης νευροεκφυλιστικές διαταραχές, όπως ασθένεια Parkinson, ασθένεια Alzheimer, διαβήτη και εστιακή ισχαιμία, εφόσον οι ασθένειες επίσης σχετίζονται προς δραστικότητα ΡΙ3Κ σε ένα υποκείμενο άνθρωπο ή υποκείμενο ζώο.
CY20091100017T 2002-09-30 2009-01-09 Παραγωγα συντηγμενου αζολιου-πυριμιδινης CY1109790T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30
EP03788908A EP1549652B1 (en) 2002-09-30 2003-09-18 Fused azole-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
CY1109790T1 true CY1109790T1 (el) 2014-09-10

Family

ID=32039115

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100017T CY1109790T1 (el) 2002-09-30 2009-01-09 Παραγωγα συντηγμενου αζολιου-πυριμιδινης
CY20111100771T CY1112174T1 (el) 2002-09-30 2011-08-10 Παραγωγα συντηγμενης αζολο-πυριμιδινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100771T CY1112174T1 (el) 2002-09-30 2011-08-10 Παραγωγα συντηγμενης αζολο-πυριμιδινης

Country Status (32)

Country Link
US (2) US7511041B2 (el)
EP (2) EP1549652B1 (el)
JP (1) JP4790266B2 (el)
KR (1) KR101059652B1 (el)
CN (1) CN100384846C (el)
AR (2) AR041426A1 (el)
AT (2) ATE411996T1 (el)
AU (1) AU2003293310B2 (el)
BR (1) BRPI0314830B8 (el)
CA (1) CA2499134C (el)
CY (2) CY1109790T1 (el)
DE (1) DE60324296D1 (el)
DK (2) DK1549652T3 (el)
EC (2) ECSP055768A (el)
ES (2) ES2312843T3 (el)
HR (2) HRP20131159B1 (el)
IL (1) IL166855A (el)
MA (1) MA27483A1 (el)
MX (1) MXPA05001808A (el)
MY (1) MY140756A (el)
NO (1) NO331457B1 (el)
NZ (1) NZ539062A (el)
PE (1) PE20050089A1 (el)
PL (1) PL226562B1 (el)
PT (2) PT2042504E (el)
RU (1) RU2326881C9 (el)
SI (2) SI1549652T1 (el)
TW (1) TWI327570B (el)
UA (1) UA82205C2 (el)
UY (1) UY28001A1 (el)
WO (1) WO2004029055A1 (el)
ZA (1) ZA200503306B (el)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN102976984B (zh) 2003-08-29 2015-04-08 三井化学株式会社 农园艺用杀虫剂的制备中间体
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
RU2403258C2 (ru) 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP3211093A1 (en) 2005-04-14 2017-08-30 The Trustees of Boston University Diagnostic for lung disorders using class prediction
BRPI0614188A2 (pt) * 2005-07-29 2011-03-15 4Sc Ag compostos inibidores heterocìclicos de nf-kappab, uso dos mesmos e composição farmacêutica
CA2645310A1 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
EP2041139B1 (en) * 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Pharmaceutical compounds
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
EP2217590A4 (en) * 2007-09-17 2011-12-14 Glaxosmithkline Llc Pyridopyrimidine derivatives as PI3-kinase inhibitors
CA2700200A1 (en) 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
US8859572B2 (en) * 2008-01-14 2014-10-14 Bayer Intellectual Property Gmbh Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
WO2009111547A1 (en) * 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
JPWO2009128520A1 (ja) * 2008-04-18 2011-08-04 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する複素環化合物
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
AU2009314760B2 (en) * 2008-11-11 2011-11-10 Je Il Pharmaceutical Co.,Ltd Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2011011036A (es) 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
ES2644724T3 (es) * 2009-04-30 2017-11-30 Glaxo Group Limited Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
JP2013504325A (ja) * 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
CN102958540B (zh) * 2010-04-16 2015-09-02 拜耳知识产权有限责任公司 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AP2013006834A0 (en) 2010-10-01 2013-04-30 Bayer Ip Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
US9730943B2 (en) 2010-11-11 2017-08-15 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9999623B2 (en) 2013-04-08 2018-06-19 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
MA42164B1 (fr) 2013-05-01 2019-12-31 Hoffmann La Roche Composes biheteroaryle et leurs utilisations
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
EP3426657B1 (en) * 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ−阻害剤の組み合わせ
WO2018112176A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft COPANLISIB FORMULATIONS
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
EP3694511A1 (en) 2017-10-13 2020-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
WO2020020385A1 (zh) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
WO2020043617A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
WO2020078788A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
EP0771204A4 (en) 1994-08-12 1999-10-20 Pro Neuron Inc METHOD FOR TREATING SEPSIS OR FLAMMABLE DISEASES WITH OXYPURINE NUCLEOSIDES
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
KR20050067404A (ko) 2005-07-01
PL226562B1 (pl) 2017-08-31
KR101059652B1 (ko) 2011-08-25
ES2312843T3 (es) 2009-03-01
EP2042504A1 (en) 2009-04-01
ES2367141T3 (es) 2011-10-28
HRP20131159B1 (hr) 2019-11-01
NZ539062A (en) 2007-05-31
AU2003293310B2 (en) 2010-04-01
TW200413379A (en) 2004-08-01
US20090270388A1 (en) 2009-10-29
CN1688582A (zh) 2005-10-26
BRPI0314830B8 (pt) 2021-05-25
ZA200503306B (en) 2006-07-26
HRP20050375B1 (hr) 2014-03-14
PL375935A1 (en) 2005-12-12
US7511041B2 (en) 2009-03-31
RU2326881C2 (ru) 2008-06-20
IL166855A (en) 2014-05-28
DE60324296D1 (de) 2008-12-04
DK2042504T3 (da) 2011-09-19
MY140756A (en) 2010-01-15
EP2042504B1 (en) 2011-06-01
NO331457B1 (no) 2012-01-09
RU2326881C9 (ru) 2009-04-10
ECSP055768A (es) 2005-08-11
SI1549652T1 (sl) 2009-04-30
BRPI0314830B1 (pt) 2018-03-27
CY1112174T1 (el) 2015-12-09
DK1549652T3 (da) 2009-02-23
UY28001A1 (es) 2004-04-30
CN100384846C (zh) 2008-04-30
JP2006508063A (ja) 2006-03-09
MXPA05001808A (es) 2005-08-16
AR041426A1 (es) 2005-05-18
MA27483A1 (fr) 2005-08-01
BR0314830A (pt) 2005-08-16
US8129386B2 (en) 2012-03-06
EP1549652A1 (en) 2005-07-06
RU2005113165A (ru) 2005-10-10
CA2499134A1 (en) 2004-04-08
WO2004029055A1 (en) 2004-04-08
AU2003293310A1 (en) 2004-04-19
SI2042504T1 (sl) 2011-10-28
US20060128732A1 (en) 2006-06-15
JP4790266B2 (ja) 2011-10-12
CA2499134C (en) 2011-12-20
HRP20131159A2 (hr) 2014-05-23
UA82205C2 (en) 2008-03-25
ECSP11005768A (es) 2011-03-31
PE20050089A1 (es) 2005-04-20
TWI327570B (en) 2010-07-21
HK1084393A1 (zh) 2006-07-28
HRP20050375A2 (en) 2006-05-31
EP1549652B1 (en) 2008-10-22
PT2042504E (pt) 2011-09-07
ATE411996T1 (de) 2008-11-15
PT1549652E (pt) 2008-12-15
ATE511510T1 (de) 2011-06-15
NO20052076L (no) 2005-04-27
AR072458A2 (es) 2010-09-01

Similar Documents

Publication Publication Date Title
CY1109790T1 (el) Παραγωγα συντηγμενου αζολιου-πυριμιδινης
CY1108746T1 (el) Παραγωγα 2-φαινοξυ- και 2-φαινυλοσουλφοναμιδιου με ανταγωνιστικη δραστικοτητα ccr3 για την θεραπεια του ασθματος και αλλων φλεγμονωδων ή ανοσολογικων διαταραχων
CY1106748T1 (el) Ν-(3,3-dimethylindolin-6-yl){2-[(4-pyridylmethyl) amino}(3-pyridyl)}carboxamide και φαρμακευτικες συνθεσεις της
CY1126056T1 (el) Νεα παραγωγα αμινοπυριμιδινης
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
MXPA04004019A (es) Derivados de pirimido?4,5-b?indol.
JOP20210017A1 (ar) مثبطات جسيم التهابي nlrp3
CY1108246T1 (el) ΠΑΡΑΓΩΓΑ 1Η-ΘΕΙΕΝΟ[2,3-c] ΠΥΡΑΖΟΛΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ
CY1111316T1 (el) Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης
EA201890650A1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
CY1109677T1 (el) Παραγωγα κινολινης και χρηση αυτων ως μυκοβακτηριακων αναστολεων
CY1115621T1 (el) Βενζοϊμιδαζολια ως αναστολεις προλυλ υδροξυλασης
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20024338D0 (no) Substituerte beta-karboliner med IKB-kinaseinhiberende aktivitet
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
MX373042B (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
EA200400476A1 (ru) Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
NO20080445L (no) Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
CY1112038T1 (el) Αναστολεις της κινασης τυροσινης
TR200103490T2 (tr) Antihistaminik ve antialerjik maddeler olarak indolilpiperidin türevleri
NO20052858D0 (no) Nye tricykliske forbindelser som LTD4-antagonister
NO20070820L (no) Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.
DOP2003000724A (es) Derivados de azol-pirimidina condensados